On June 24, SPYRE THERAPEUTICS fell 10.83% in pre-market trading, trading at $86.54 USD/share, with Turnover of $17,500.
Within the Biotechnology sector where SPYRE THERAPEUTICS belongs, individual stock performance was mixed. Among individual stocks, Apogee Therapeutics up 1.44%, AbbVie up 0.63%, Regeneron Pharmaceuticals up 0%, Gilead Sciences down 0.14%, Amgen down 0.58%.
SPYRE THERAPEUTICS is a preclinical stage biotechnology company focused on developing therapeutics for patients with inflammatory bowel disease (IBD). Its product pipeline includes SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23), along with combination therapies SPY120, SPY130, and SPY230.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments